Management strategies for acute spinal cord injury: Current options and future perspectives

Current Opinion in Critical Care

Volumn 18, Issue 6, 2012, Pages 651-660

  Stahel, Philip F ^a   Vanderheiden, Todd ^a   Finn, Michael A ^a  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

axonal regeneration; Nogo A; spinal cord injury; spine damage control

Indexed keywords

ATI 355; CORTICOSTEROID; FIBRIC ACID DERIVATIVE; GLITAZONE DERIVATIVE; METHYLPREDNISOLONE; NOGO A ANTIBODY; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PLACEBO; PROTEIN NOGO A; UNCLASSIFIED DRUG;

BLEEDING; BLOOD PRESSURE REGULATION; BREATHING; COMPLEMENT INHIBITION; COMPUTER ASSISTED TOMOGRAPHY; CONVALESCENCE; CORTICOSTEROID THERAPY; DRUG EFFICACY; DRUG FATALITY; DRUG MEGADOSE; DRUG SAFETY; EMERGENCY CARE; FRACTURE IMMOBILIZATION; HUMAN; INDUCED HYPOTHERMIA; INJURY SCALE; INJURY SEVERITY; NERVE CELL PLASTICITY; NERVE FIBER GROWTH; NERVE FIBER REGENERATION; NERVOUS SYSTEM INFLAMMATION; NEUROPATHOLOGY; NON INVASIVE PROCEDURE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OPEN REDUCTION; PRACTICE GUIDELINE; RESPIRATORY CARE; REVIEW; SPINAL CORD DECOMPRESSION; SPINAL CORD INJURY; SPINE FRACTURE; SPINE STABILIZATION; TISSUE OXYGENATION;

CENTRAL NERVOUS SYSTEM; COMBINED MODALITY THERAPY; FEMALE; GROWTH INHIBITORS; HUMANS; HYPOTHERMIA, INDUCED; IMMOBILIZATION; MALE; MYELIN PROTEINS; PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS; SPINAL CORD INJURIES; STEROIDS; UNITED STATES;

EID: 84870249383     PISSN: 10705295     EISSN: 15317072     Source Type: Journal    
DOI: 10.1097/MCC.0b013e32835a0e54     Document Type: Review

References (111)

1. Post MW, van Leeuwen CM. Psychosocial issues in spinal cord injury: a review. Spinal Cord 2012; 50:382-389.
2. Shin JC, Goo HR, Yu SJ, et al. Depression and quality of life in patients within the first 6 months after the spinal cord injury. Ann Rehabil Med 2012; 36:119-125.
3. Livecchi MA. Spinal cord injury. Continuum (Minneap Minn) 2011; 17:568-583.
4. Devivo MJ. Epidemiology of traumatic spinal cord injury: trends and future implications. Spinal Cord 2012; 50:365-372.
5. Court-Brown CM, Caesar B. Epidemiology of adult fractures: a review. Injury 2006; 37:691-697. (Pubitemid 44066989)
6. Stahel PF. Initial management of patients with traumatic spinal cord injuries. Orthopedics (in press).
7. Hogel F, Mach O, Maier D. Functional outcome of patients 12 and 48 weeks after acute traumatic tetraplegia and paraplegia: data analysis from 2004-2009. Spinal Cord 2012; 50:517-520.
8. Marsh JL, Slongo TF, Agel J, et al. Fracture and dislocation classification compendium - 2007: Orthopaedic Trauma Association classification, database and outcomes committee. J Orthop Trauma 2007; 21 (Suppl 10): S1-S133. (Pubitemid 351253435)
9. Stahel PF, Flierl MA, Matava B. Traumatic spondylolisthesis. In: Vincent JL, Hall J, editors. Encyclopedia of intensive care, medicine. Heidelberg: Springer; 2012 (in press).
10. Yadla S, Lebude B, Tender GC, et al. Traumatic spondyloptosis of the thoracolumbar spine. J Neurosurg Spine 2008; 9:145-151.
11. Flierl MA, Beauchamp KM, Dwyer A, Stahel PF. Immunological response to spinal cord injury: impact on the timing of spine surgery. In: Patel VV, Burger E, Brown C, editors. Spine Trauma. Berlin/Heidelberg: Springer; 2010. pp. 73-83.
12. Stahel PF, Flierl MA. Targeted modulation of the neuroinflammatory response after spinal cord injury: the ongoing quest for the 'holy grail'. Am J Pathol 2010; 177:2685-2687.
13. Borgens RB, Liu-Snyder P. Understanding secondary injury. Q Rev Biol 2012; 87:89-127.
14. Austin JW, Afshar M, Fehlings MG. The relationship between localized subarachnoid inflammation and parenchymal pathophysiology after spinal cord injury. J Neurotrauma 2012; 29:1838-1849.
15. Bethea JR, Dietrich WD. Targeting the host inflammatory response in traumatic spinal cord injury. Curr Opin Neurol 2002; 15:355-360. (Pubitemid 34596902)
16. Bareyre FM, Schwab ME. Inflammation, degeneration and regeneration in the injured spinal cord: insights from DNA microarrays. Trends Neurosci 2003; 26:555-563. (Pubitemid 37176911)
17. Jones TB, McDaniel EE, Popovich PG. Inflammatory-mediated injury and repair in the traumatically injured spinal cord. Curr Pharm Des 2005; 11:1223-1236. (Pubitemid 40458268)
18. Olson JK. Immune response by microglia in the spinal cord. Ann NY Acad Sci 2010; 1198:271-278.
19. Boekhoff TM, Ensinger EM, Carlson R, et al. Microglial contribution to secondary injury evaluated in a large animal model of human spinal cord trauma. J Neurotrauma 2012; 29:1000-1011.
20. Qiao F, Atkinson C, Song H, et al. Complement plays an important role in spinal cord injury and represents a therapeutic target for improving recovery following trauma. Am J Pathol 2006; 169:1039-1047. (Pubitemid 44411965)
21. Qiao F, Atkinson C, Kindy MS, et al. The alternative and terminal pathways of complement mediate posttraumatic spinal cord inflammation and injury. Am J Pathol 2010; 177:3061-3070.
22. Stahel PF, Smith WR, Moore EE. Role of biological modifiers regulating the immune response after trauma. Injury 2007; 38:1409-1422. (Pubitemid 350192403)
23. Li LM, Li JB, Zhu Y, Fan GY. Soluble complement receptor type 1 inhibits complement system activation and improves motor function in acute spinal cord injury. Spinal Cord 2010; 48:105-111.
24. Stahel PF, Barnum SR. The role of the complement system in CNS inflammatory diseases. Expert Rev Clin Immunol 2006; 2:445-456. (Pubitemid 44355575)
25. Lee SM, Rosen S, Weinstein P, et al. Prevention of both neutrophil and monocyte recruitment promotes recovery after spinal cord injury. J Neurotrauma 2011; 28:1893-1907.
26. Geremia NM, Bao F, Rosenzweig TE, et al. CD11d antibody treatment improves recovery in spinal cord-injured mice. J Neurotrauma 2012; 29:539-550.
27. Nataf S, Stahel PF, Davoust N, Barnum SR. Complement anaphylatoxin receptors on neurons: new tricks for old receptors? Trends Neurosci 1999; 22:397-402. (Pubitemid 29453644)
28. Kubota K, Saiwai H, Kumamaru H, et al. Myeloperoxidase exacerbates secondary injury by generating highly reactive oxygen species and mediating neutrophil recruitment in experimental spinal cord injury. Spine (Phila Pa 1976) 2012; 37:1363-1369.
29. Veeravalli KK, Dasari VR, Rao JS. Regulation of proteases after spinal cord injury. J Neurotrauma 2012; 29:2251-2262.
30. Jia Z, Zhu H, Li J, et al. Oxidative stress in spinal cord injury and antioxidant-based intervention. Spinal Cord 2012; 50:264-274.
31. Maggio DM, Chatzipanteli K, Masters N, et al. Acute molecular perturbation of inducible nitric oxide synthase with an antisense approach enhances neuronal preservation and functional recovery after contusive spinal cord injury. J Neurotrauma 2012; 29:2244-2249.
32. Bains M, Hall ED. Antioxidant therapies in traumatic brain and spinal cord injury. Biochim Biophys Acta 2012; 1822:675-684.
33. Maikos JT, Shreiber DI. Immediate damage to the blood-spinal cord barrier due to mechanical trauma. J Neurotrauma 2007; 24:492-507. (Pubitemid 46598283)
34. Bartanusz V, Jezova D, Alajajian B, Digicaylioglu M. The blood-spinal cord barrier: morphology and clinical implications. Ann Neurol 2011; 70:194-206.
35. Peter NR, Shah RT, Chen J, et al. Adhesion molecules close homolog of L1 and tenascin-C affect blood-spinal cord barrier repair. Neuroreport 2012; 23:479-482.
36. Zhang H, Chang M, Hansen CN, et al. Role of matrix metalloproteinases and therapeutic benefits of their inhibition in spinal cord injury. Neurotherapeutics 2011; 8:206-220.
37. Lee JY, Kim HS, Choi HY, et al. Valproic acid attenuates blood-spinal cord barrier disruption by inhibiting matrix metalloprotease-9 activity and improves functional recovery after spinal cord injury. J Neurochem 2012; 121:818-829.
38. Courtine G, van den Brand R, Musienko P. Spinal cord injury: time to move. Lancet 2011; 377:1896-1898.
39. Kuffler DP. Maximizing neuroprotection: where do we stand? Ther Clin Risk Manag 2012; 8:185-194.
40. Markandaya M, Stein DM, Menaker J. Acute treatment options for spinal cord injury. Curr Treat Options Neurol 2012 [Epub ahead of print].
41. Stahel PF, Smith WR, Moore EE. Current trends in resuscitation strategy for the multiply injured patient. Injury 2009; 40 (Suppl 4):S27-S35.
42. American College of Surgeons Committee on Trauma. Advanced trauma life support (ATLS). Student course manual, 8th ed. Chicago, IL: American College of Surgeons; 2008.
43. Schouten R, Albert T, Kwon BK. The spine-injured patient: initial assessment and emergency treatment. J Am Acad Orthop Surg 2012; 20:336-346.
44. Stahel PF, Heyde CE, Flierl MA. Head and neck injuries. In: Wilkerson JA, Moore EE, Zafren K, editors. Medicine for mountaineering and other wilderness activities, 6th ed Seattle, WA: The Mountaineers Books; 2010. pp. 86-95.
45. Ahn H, Singh J, Nathens A, et al. Prehospital care management of a potential spinal cord injured patient: a systematic review of the literature and evidence-based guidelines. J Neurotrauma 2011; 28:1341-1361.
46. Liu YS, Feng YP, Xie JX, et al. A novel first aid stretcher for immobilization and transportation of spine injured patients. PLoS One 2012; 7:e39544.
47. Kwan I, Bunn F, Roberts I. Spinal immobilisation for trauma patients. Cochrane Database Syst Rev 2001:CD002803.
48. Como JJ, Leukhardt WH, Anderson JS, et al. Computed tomography alone may clear the cervical spine in obtunded blunt trauma patients: a prospective evaluation of a revised protocol. J Trauma 2011; 70:345-349.
49. Harris MB, Sethi RK. The initial assessment and management of the multipletrauma patient with an associated spine injury. Spine (Phila Pa 1976) 2006; 31 (Suppl 11):S9-S15.
50. Aarabi B, Simard JM, Kufera JA, et al. Intramedullary lesion expansion on magnetic resonance imaging in patients with motor complete cervical spinal cord injury. J Neurosurg Spine 2012. [Epub ahead of print]
51. Albrecht T, von Schlippenbach J, Stahel PF, et al. The role of whole body spiral CT in the primary work-up of polytrauma patients - comparison with conventional radiography and abdominal sonography. Rofo 2004; 176:1142-1150. (Pubitemid 39118856)
52. Panczykowski DM, Tomycz ND, Okonkwo DO. Comparative effectiveness of using computed tomography alone to exclude cervical spine injuries in obtunded or intubated patients: meta-analysis of 14,327 patients with blunt trauma. J Neurosurg 2011; 115:541-549.
53. Kossmann T, Payne B, Stahel PF, Trentz O. Traumatic paraplegia: surgical measures. Swiss Med Wkly 2000; 130:816-828.
54. Weckbach S, Flierl MA, Blei M, et al. Survival following a vertical free fall from 300 feet: the crucial role of body position to impact surface. Scand J Trauma Resusc Emerg Med 2011; 19:63.
55. Yan D, Wang Z, Lv Y, et al. Anterior versus posterior surgical treatment of unstable thoracolumbar burst fractures. Eur J Orthop Surg Traumatol 2012; 22:103-109.
56. Carreon LY, Dimar JR. Early versus late stabilization of spine injuries: a systematic review. Spine (Phila Pa 1976) 2011; 36:E727-E733.
57. Schinkel C, Anastasiadis AP. The timing of spinal stabilization in polytrauma and in patients with spinal cord injury. Curr Opin Crit Care 2008; 14:685-689.
58. Schmidt OI, Gahr RH, Gosse A, Heyde CE. ATLS and damage control in spine trauma. World J Emerg Surg 2009; 4:9.
59. Stahel PF, Vanderheiden T, Flierl MA, et al. The impact of a standardized 'spine damage control' protocol for unstable thoracic and lumbar spine fractures in severely injured patients: a prospective cohort study. J Trauma Acute Care Surg (in press).
60. Stahel PF, Flierl MA, Moore EE, et al. Advocating 'spine damage control' as a safe and effective treatment modality for unstable thoracolumbar fractures in polytrauma patients: a hypothesis. J Trauma Manag Outcomes 2009; 3:6.
61. Bellabarba C, Fisher C, Chapman JR, et al. Does early fracture fixation of thoracolumbar spine fractures decrease morbidity or mortality? Spine (Phila Pa 1976) 2010; 35 (Suppl 9):S138-S145.
62. Buchli AD, Rouiller E, Mueller R, et al. Repair of the injured spinal cord. A joint approach of basic and clinical research. Neurodegener Dis 2007; 4:51-56. (Pubitemid 46586560)
63. Kwon BK, Okon E, Hillyer J, et al. A systematic review of noninvasive pharmacologic neuroprotective treatments for acute spinal cord injury. J Neurotrauma 2011; 28:1545-1588.
64. Nout YS, Rosenzweig ES, Brock JH, et al. Animal models of neurologic disorders: a nonhuman primate model of spinal cord injury. Neurotherapeutics 2012; 9:380-392.
65. Lee RS, Noonan VK, Batke J, et al. Feasibility of patient recruitment into clinical trials of experimental treatments for acute spinal cord injury. J Clin Neurosci 2012; 19:1338-1343.
66. van den Brand R, Heutschi J, Barraud Q, et al. Restoring voluntary control of locomotion after paralyzing spinal cord injury. Science 2012; 336:1182-1185.
67. Mortazavi MM, Verma K, Tubbs RS, Theodore N. Nonpharmacological experimental treatments for spinal cord injury: a review. Childs Nerv Syst 2012 [Epub ahead of print].
68. Maybhate A, Hu C, Bazley FA, et al. Potential long-term benefits of acute hypothermia after spinal cord injury: assessments with somatosensoryevoked potentials. Crit Care Med 2012; 40:573-579.
69. Straus D, Prasad V, Munoz L. Selective therapeutic hypothermia: a review of invasive and noninvasive techniques. Arq Neuropsiquiatr 2011; 69:981-987.
70. Cappuccino A, Bisson LJ, Carpenter B, et al. The use of systemic hypothermia for the treatment of an acute cervical spinal cord injury in a professional football player. Spine (Phila Pa 1976) 2010; 35:E57-E62.
71. Beauchamp KM, Flierl MA, Stahel PF. Re: The use of systemic hypothermia for the treatment of an acute cervical spinal cord injury in a professional football player. Spine (Phila Pa 1976) 2010; 35:1827-1828.
72. Marion DW, Penrod LE, Kelsey SF, et al. Treatment of traumatic brain injury with moderate hypothermia. N Engl J Med 1997; 336:540-546. (Pubitemid 27085734)
73. Urbano LA, Oddo M. Therapeutic hypothermia for traumatic brain injury. Curr Neurol Neurosci Rep 2012; 12:580-591.
74. Hurlbert RJ. Methylprednisolone for acute spinal cord injury: an inappropriate standard of care. J Neurosurg 2000; 93 (Suppl 1):1-7.
75. Hurlbert RJ, Hamilton MG. Methylprednisolone for acute spinal cord injury: 5-year practice reversal. Can J Neurol Sci 2008; 35:41-45. (Pubitemid 351518287)
76. Bracken MB. Steroids for acute spinal cord injury. Cochrane Database Syst Rev 2012:CD001046.
77. Ghallich JH. The use of dexamethasone in the treatment of cerebral edema resulting from brain tumors and brain surgery. Am Pract Dig Treat 1961; 12:169-174.
78. Bracken MB, Shepard MJ, Collins WF, et al. A randomized, controlled trial of methylprednisolone or naloxone in the treatment of acute spinal-cord injury. Results of the Second National Acute Spinal Cord Injury Study. N Engl J Med 1990; 322:1405-1411. (Pubitemid 20152525)
79. Bracken MB, Holford TR. Neurological and functional status 1 year after acute spinal cord injury: estimates of functional recovery in National Acute Spinal Cord Injury Study II from results modeled in National Acute Spinal Cord Injury Study III. J Neurosurg 2002; 96 (3 Suppl):259-266. (Pubitemid 34245645)
80. Roberts I, Yates D, Sandercock P, et al. Effect of intravenous corticosteroids on death within 14 days in 10008 adults with clinically significant head injury (MRC CRASH trial): randomised placebo-controlled trial. Lancet 2004; 364:1321-1328.
81. Sauerland S, Maegele M. A CRASH landing in severe head injury. Lancet 2004; 364:1291-1292. (Pubitemid 39335807)
82. Schwab ME. Nogo and axon regeneration. Curr Opin Neurobiol 2004; 14:118-124. (Pubitemid 38264581)
83. Huber AB, Schwab ME. Nogo-A: a potent inhibitor of neurite outgrowth and regeneration. Biol Chem 2000; 381:407-419. (Pubitemid 30453817)
84. Zörner B, Schwab ME. Anti-Nogo on the go: from animal models to a clinical trial. Ann NY Acad Sci 2010; 1198 (Suppl 1):E22-E34.
85. Pernet V, Schwab ME. The role of Nogo-A in axonal plasticity, regrowth and repair. Cell Tissue Res 2012; 349:97-104.
86. Simonen M, Pedersen V, Weinmann O, et al. Systemic deletion of the myelin-associated outgrowth inhibitor Nogo-A improves regenerative and plastic responses after spinal cord injury. Neuron 2003; 38:201-211. (Pubitemid 36555647)
87. Kim JE, Li S, Grand Pre T, et al. Axon regeneration in young adult mice lacking Nogo-A/B. Neuron 2003; 38:187-199. (Pubitemid 36555646)
88. Liebscher T, Schnell L, Schnell D , et al. Nogo-A antibody improves regeneration and locomotion of spinal cord-injured rats. Ann Neurol 2005; 58:706-719. (Pubitemid 41552546)
89. Freund P, Schmidlin E, Wannier T, et al. Nogo-A-specific antibody treatment enhances sprouting and functional recovery after cervical lesion in adult primates. Nat Med 2006; 12:790-792. (Pubitemid 44050068)
90. Ozdemir M, Attar A, Kuzu I. Regenerative treatment in spinal cord injury. Curr Stem Cell Res Ther 2012 [Epub ahead of print].
91. Quertainmont R, Cantinieaux D, Botman O, et al. Mesenchymal stem cell graft improves recovery after spinal cord injury in adult rats through neurotrophic and pro-angiogenic actions. PLoS One 2012; 7:e39500.
92. Yazdani SO, Pedram M, Hafizi M, et al. A comparison between neurally induced bone marrow derived mesenchymal stem cells and olfactory ensheathing glial cells to repair spinal cord injuries in rat. Tissue Cell 2012; 44:205-213.
93. Kang KN, Kim da Y, Yoon SM, et al. Tissue engineered regeneration of completely transected spinal cord using human mesenchymal stem cells. Biomaterials 2012; 33:4828-4835.
94. Park HW, Cho JS, Park CK, et al. Directed induction of functional motor neuron-like cells from genetically engineered human mesenchymal stem cells. PLoS One 2012; 7:e35244.
95. Hwang DH, Kim HM, Kang YM, et al. Combination of multifaceted strategies to maximize the therapeutic benefits of neural stem cell transplantation for spinal cord repair. Cell Transplant 2011; 20:1361-1379.
96. Huang Y, Qiao F, Atkinson C, et al. A novel targeted inhibitor of the alternative pathway of complement and its therapeutic application in ischemia/reperfusion injury. J Immunol 2008; 181:8068-8076.
97. Fridkis-Hareli M, Storek M, Mazsaroff I, et al. Design and development of TT30, a novel C3d-targeted C3/C5 convertase inhibitor for treatment of human complement alternative pathway-mediated diseases. Blood 2011; 118:4705-4713.
98. Neher M, Weckbach S, Flierl MA, et al. Molecular mechanisms of inflammation and tissue injury after major trauma - is complement the 'bad guy'? J Biomed Sci 2011; 18:90.
99. Stahel PF, Smith WR, Bruchis J, Rabb CH. Peroxisome proliferator- activated receptors: 'key' regulators of neuroinflammation after traumatic brain injury. PPAR Res 2008; 2008:538141.
100. Willson TM, Brown PJ, Sternbach DD, Henke BR. The PPARs: from orphan receptors to drug discovery. J Med Chem 2000; 43:527-550. (Pubitemid 30127149)
101. Abdelrahman M, Sivarajah A, Thiemermann C. Beneficial effects of PPAR-gamma ligands in ischemia-reperfusion injury, inflammation and shock. Cardiovasc Res 2005; 65:772-781. (Pubitemid 40249723)
102. Almad A, McTigue DM. Chronic expression of PPAR-delta by oligodendrocyte lineage cells in the injured rat spinal cord. J Comp Neurol 2010; 518:785-799.
103. Neher MD, Weckbach S, Huber-Lang MS, Stahel PF. New insights into the role of peroxisome proliferator-activated receptors in regulating the inflammatory response after tissue injury. PPAR Res 2012; 2012:728461.
104. Lalloyer F, Staels B. Fibrates, glitazones, and peroxisome proliferator-activated receptors. Arterioscler Thromb Vasc Biol 2010; 30:894-899.
105. Esposito E, Cuzzocrea S. Targeting the peroxisome proliferator-activated receptors (PPARs) in spinal cord injury. Expert Opin Ther Targets 2011; 15:943-959.
106. Meng QQ, Liang XJ, Wang P, et al. Rosiglitazone enhances the proliferation of neural progenitor cells and inhibits inflammation response after spinal cord injury. Neurosci Lett 2011; 503:191-195.
107. Meng B, Zhang Q, Huang C, et al. Effects of a single dose of methylprednisolone versus three doses of rosiglitazone on nerve growth factor levels after spinal cord injury. J Int Med Res 2011; 39:805-814.
108. Esposito E, Paterniti I, Meli R, et al. GW0742, a high-affinity PPAR-delta agonist, mediates protection in an organotypic model of spinal cord damage. Spine (Phila Pa 1976) 2012; 37:E73-E78.
109. Zhang Q, Huang C, Tang T, et al. Comparative neuroprotective effects of methylprednisolone and rosiglitazone, a peroxisome proliferator-activated receptor-gamma following spinal cord injury. Neurosciences (Riyadh) 2011; 16:46-52.
110. Zhang Q, Hu W, Meng B, Tang T. PPARg agonist rosiglitazone is neuroprotective after traumatic spinal cord injury in adult rats. Neurol Res 2010; 32:852-859.
111. Paterniti I, Esposito E, Mazzon E, et al. Evidence for the role of peroxisome proliferator-activated receptor-beta/delta in the development of spinal cord injury. J Pharmacol Exp Ther 2010; 333:465-477.